Medlab is proud to present at the 2021 Australian Pain Society 41st Annual Scientific Meeting, on the 19th of April.
Preliminary analgesic evidence of cannabinoids delivered via NanoCelle® (submicron particle technology) and its further research addressing gaps in cannabis dosing efficacy.
Results of a completed clinical study at RNSH investigating the pharmacokinetics (PK), safety, and tolerability of THC and CBD cannabinoids in a unique NanoCelle® formulation for the management of unrelieved pain in patients diagnosed with advanced cancers. Medlab’s water-soluble nanoparticle delivered cannabis-based medicine showed superior bioavailability and tolerability compared to ethanol-based delivery of cannabis-based medicines across the oro-buccal mucous membrane. The results of the study have demonstrated acceptable bioavailability, safety, tolerability, and evidence of analgesic efficacy in advanced cancers with bone metastasis.
- Results published in the Asia Pacific Journal of Clinical Oncology. #219 https://onlinelibrary.wiley.com/doi/10.1111/ajco.13498
- Preparations to run phase III trial AU, UK and US
Presenting an update on current research is important for those physicians who are currently prescribing medicinal cannabis for the patients where traditional therapies have failed. The level of current evidence on medicinal cannabis efficacy is low to moderate, and further research is needed for the safety of patients.
Location - Virtual
Time - 8:00am - 9:00am
Dates - 19 April 2021